Business
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- -- Rapid engraftment observed in both neutrophils and platelets -- -- Encouraging safety profile; no serious adverse events related to PM359 -- -- Initiating efforts to explore continued clinical development oppo
About this update from Prime Medicine, Inc.
[{"type":"image","alt":"Prime Medicine, Inc.","displaySize":"","headline":null,"caption":"Prime Medicine, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/7c5397d80babf7cd71ba3f6a787c0b3f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/S_7U4Aj8CXur3GvYQq2zOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7c5397d80babf7cd71ba3f6a787c0b3f","width":300,"height":100}},"lazy":false},{"type":"text","content":"-- First ever clinical data supporting safety and efficacy of Prime Editing in humans --","length":88,"tagName":"p"},{"type":"text","content":"-- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --","length":198,"tagName":"p"},{"type":"text","content":"-- Rapid engraftment observed in both neutrophils and platelets --","length":66,"tagName":"p"},{"type":"text","content":"-- Encouraging safety profile; no serious adverse events related to PM359 --","length":76,"tagName":"p"},{"type":"text","content":"-- Initiating efforts to explore continued clinical development opportunities for PM359 external to Prime Medicine --","length":117,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 in Chronic Granulomatous Disease (CGD). Preliminary results from the first patient demonstrated that PM359 was well-tolerated, showed rapid engraftment and restored NADPH oxidase activity to well above the threshold for clinical benefit, as measured by the dihydrorhodamine (DHR) assay.","length":605,"tagName":"p"},{"type":"text","content":"CGD is a rare inherited disease that leads to recurrent, debilitating and often life-threatening infections. It is caused by mutations in genes, including NCF1, that encode proteins that form the NADPH oxidase complex, an enzyme that kills bacteria and fungi to control infection. PM359, an ex vivo Prime Edited autologous hematopoietic stem cell (HS...